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Dear Editor,
Multiple endocrine neoplasia type 2 (MEN2) is a rare 
syndrome subdivided into 2 main entities: MEN2A 
and MEN2B (Donis-Keller  et  al. 1993, Mulligan  et  al. 
1993, Eng  et  al. 1996). Genetic results can predict the 
natural history of medullary thyroid carcinoma (MTC) 
depending on the mutation of RET. This is the basis for 
ATA guidelines giving different ages to perform early 
thyroidectomy in such patients (Wells  et  al. 2015). 
MEN2A and MEN2B are also characterized by the 
occurrence of pheochromocytoma (PHEO), though less 
frequent than MTC. PHEO is a chromaffin tumor arising 
from the medullar zone of the adrenals and responsible 
for mortality if left undiagnosed (Lenders  et  al. 2005). 
Precise comparative large-scale epidemiological data 
on PHEO penetrance in different geographical zones 
are however missing in the literature as the majority of 
published studies were coming from a single Center or a 
single country.
To further describe the natural history of MEN2A 
PHEO, investigators from South America (Argentina, 
Chile, Brazil), Southern Europe (Italy, Spain, Portugal, 
Greece), Western Europe (France, Germany, The 
Netherlands) and Central Europe (Ukraine, Poland, 
Slovenia, Czech Republic) were contacted and asked to 
retrospectively collect demographic, clinical and genetic 
data about PHEO in MEN2 patients carrying mutations in 
exons 10 and 11 of RET. The aim was to better characterize 
the main epidemiological characteristics of MEN2 
PHEO in these 4 different geographical areas. Follow-up 
policy was the same for all Centres: plasma and/or 
urinary metanephrine measurements were performed in 
symptomatic patients or in asymptomatic patients every 
6–12 months depending on each investigator; imaging was 
done systematically when metanephrine concentrations 
increased, and every 3–5  years in patients with normal 
metanephrine values based upon investigators’ decision. 
In accordance with the institutional review board, all 
patients provided signed written informed consent for 
genetics and analyses of the results. Exceptions for this 
second point were the centers in Groningen and Utrecht 
in the Netherlands, and Lisbon in Portugal, where the 
participants’ identities were anonymized and protected 
by unique codes that were known only by two dedicated 
data managers; therefore, no further institutional review 
board approval was needed at these centers. The database 
was established from November 1, 2012 to October 1, 
2013. Full characterization of the database was previously 
reported (Castinetti et al. 2014). Patients included in the 
database were enrolled at the participating centers from 
1968 to 2013. Patients included in the database had to be 
diagnosed as carriers of germline pathogenic mutations of 
RET. Additionally, first-degree relatives with histologically 
proven MTC and PHEO (defined by the association of 
increased urinary or plasma metanephrines and adrenal 
tumor) were included.
Continuous variables are presented as median (IQR). 
Age-dependent penetrance estimates of PHEO were 
performed with the Kaplan–Meier method: we compared 
disease-free survival with the log-rank analysis. Statistical 
comparisons of quantitative data were performed with 
Student’s t test or ANOVA. For dichotomous data, χ2 
test was used. All statistical tests were two sided, and 
P values of less than 0.05 were considered significant. 
Analyses were done with PRISM 6 software (GraphPad 
Software, 2014).
The cohort included 812 patients (446 females, 366 
males) with MEN2A due to RET mutations in exons 
10 and 11. Genetic analysis of the whole cohort showed 
that 239 patients (29%) carried exon 10 mutations and 
573 patients (71%) exon 11 mutations (RET 634 codon). 
At last follow-up, 462 patients (56.9%) were presenting 
with at least 1 PHEO, while 350 (43.1%) were safe of 
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PHEO (with negative biochemistry) at a median age 
of 35  years (min, 6; max, 87). Among the 462 patients 
with at least 1 PHEO, 412 carried mutations in exon 11 
(71.9% of the 573 patients with RET 634) while 50 carried 
mutations in exon 10 (20.9% of 239 patients) (P < 0.001 
for exon 10 vs exons 11). Median age at first diagnosis was 
42 (IQR, 17) and 34 (IQR, 18) years for exons 10 and 11 
respectively (P < 0.001 for exon 10 vs exons 11, data not 
shown). At least 1 pheochromocytoma was observed 
in 50% of patients with exon 11 by age 38 years, while 
the same penetrance was observed in 50% of patients 
with exon 10 by age 65 (P < 0.0001, data not shown). 
At last follow-up, 290 patients (62.8%) had bilateral 
pheochromocytoma: 210 (72.5%) presented synchronous 
bilateral pheochromocytoma, while 80 (27.5%) presented 
metachronous bilateral pheochromocytoma after a 
median time of 72 months (IQR, 84). Among these 290 
patients, 270 carried exon 11 (93.1%) while 20  carried 
exon 10 (6.9%) (P < 0.001). Interestingly, among 
patients with exon 10 and 11 mutations, there was no 
significant difference in the median age at first diagnosis 
of pheochromocytoma whatever the codon or the 
amino-acid substitution (P = 0.207, data not shown).
We subdivided the whole cohort of patients into 
4 different geographical areas: South America (n = 268), 
Southern Europe (n = 178), Western Europe (n = 192) and 
Central Europe (n = 174) to determine the phenotypic 
characteristics of MEN2 pheochromocytoma in each 
area. There was a significant difference in the number 
of patients with pheochromocytoma and exons 10 
(codon 620) and 11 (codon 634) mutations as shown 
in Table 1. At last follow-up (not significantly different 
between all areas), for exon 11, only 53% of patients 
had presented at least 1 pheochromocytoma in 
South America, while they were 75–81% in the other 3 
areas (P = 0.038). There was a significant difference for 
unilateral and bilateral pheochromocytoma penetrance 
between South America and the 3 European areas: 50% 
of patients presented unilateral pheochromocytoma at 
33, 36, 37 and 43 and bilateral pheochromocytoma at 
44, 44, 45 and 61 years of age, respectively, in Southern 
Europe, Central Europe, Western Europe and South 
America (P < 0.0001, P = 0.0017 for South America vs 
other areas) (Fig. 1).
Our data are of importance mainly because PHEO has 
progressively become the main MEN2A disease: Indeed, 
early thyroidectomy has modified the outcome of MEN2 
Table 1 Characteristics of pheochromocytoma based on geographic area.
 Southern Europe Central Europe Western Europe South America P
Patients 185 174 190 263  
Pheochromocytoma 93 (52%) 118 (68%) 141 (74%) 110 (41%) 0.038
 Unilateral 35 (38%) 44 (37%) 45 (32%) 44%) ns
 Bilateral 58 (62%) 74 (63%) 96 (68%) 56%) ns
  Synchronous 51 (88%) 48 (65%) 70 (73%) 42 (68%) 0.012
  Metachronous 7 (12%) 26 (35%) 26 (27%) 20 (32%) 0.016
Patients with mutations in      
 Exon 10 17/90 (19%) 9/35 (25%) 15/36 (42%) 9/78 (12%) 0.021
 Exon 11 76/95 (81%) 109/139 (75%) 126/154 (81%) 101/185 (53%) 0.033
Patients with mutations in codon      
 609 3/25 (12%) 3/10 (30%) 3/4 (75%) 0/0 ns
 611 2/2 (100%) 1/6 (17%) 3/3 (100%) 0/6 ns
 618 3/18 (17%) 3/11 (27%) 8/27 (30%) 4/17 (25%) ns
 620 9/45 (20%) 2/8 (25%) 1/2 (50%) 5/55 (9%) 0.049
 634 76/95 (80%) 109/139 (78%) 126/154 (81%) 101/185 (55%) 0.038
Mean age at last follow-up (years) (min–max) 45 (12–90) 42 (7–79) 51 (6–95) 43 (7–96) ns
Gender, male/female. For RET exon and codon lines, the rate represents the number of patients with pheochromocytoma vs the total number of patients.
Figure 1
Bilateral pheochromocytoma penetrance in patients with RET 634 
mutation based on geographic area. The table shows the number of 
subjects at risk initially, and then at 20 and 40 years of age. There was a 
significant difference in terms of penetrance depending on the 
geographical area (P < 0.0001 for unilateral PHEO, P = 0.0017 for  
bilateral PHEO).
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patients in the way that endocrinologists taking care 
of familial cases identified by early genetic screening 
will mainly have to deal with PHEO follow-up and 
management (Waguespack et al. 2011). MEN2 PHEO can 
be diagnosed in a same way as sporadic PHEO with the 
main advantage of being usually discovered at an early 
stage due to the regular follow-up of MEN2 patients. We 
recently reported that patients with MEN2 PHEO could 
take benefit of adrenal sparing surgery, a technique aimed 
at sparing a piece of cortical tissue while taking off the 
PHEO, allowing for a normal post-surgical cortical function 
in more than 50% of patients (Castinetti  et  al. 2014). 
A proper follow-up of MEN2 patients is thus mandatory to 
optimize their treatment: as such, endocrinologists need 
to know perfectly the natural history of MEN2 PHEO, 
but specific series on pheochromocytoma are lacking 
(Imai et al. 2013, Thosani et al. 2013).
Our study emphasizes the fact that RET mutation is 
not the only determinant of the natural history of PHEO 
in MEN2. Indeed, we report for the first time a different 
natural history of MEN2 PHEO between Europe and South 
America. As all the centers had the same policy in terms 
of PHEO follow-up, this difference cannot be explained 
by different diagnostic approaches. The difference is 
highly significant: 50% of Central Europe patients will 
have a PHEO by age 33 years, while it is only by the age 
of 43  years that the same percent will be obtained in 
South America. More importantly from a management 
viewpoint, a delay of more than 15 years was observed 
between the age at which patients would present 
bilateral PHEO (and thus a definite adrenal insufficiency 
when treated by bilateral adrenalectomy) in Europe vs 
South America. This could be due to modifier variants 
in RET or in another gene: Siqueira and coworkers had 
suggested that RET polymorphisms (L769L, S836S, and 
G691S/S904S) might modify the natural history of MEN2 
PHEO: patients with 2 of these polymorphisms indeed 
presented a younger age at diagnosis (Siqueira  et  al. 
2014). Protective alleles could also explain this different 
natural history: protective alleles are rare and potentially 
ancestry specific, and in our cohort, they could be 
identified in patients from South America. To further 
ascertain this hypothesis, large multiethnic studies 
should be performed. Finally, one further explanation 
could also be the influence of the environment, but this 
remains hypothetical for MEN2.
To conclude, the differences reported in this study 
thus suggest that the natural history of MEN2 PHEO 
could be influenced by modifying factors (genetic or 
environmental). Future studies should be aimed at better 
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defining these factors, now that the main epidemiological 
characteristics of MEN2 PHEO have been well defined.
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